Viking Therapeutics (VKTX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for May 19, 2026, to be held virtually, with voting on director elections, auditor ratification, and executive compensation approval.

• Record date for voting is March 20, 2026; only shareholders of record on this date may vote.

• Proxy materials are available online, with options for electronic, phone, or mail voting.

Voting matters and shareholder proposals

• Shareholders will vote to elect two Class II directors (J. Matthew Singleton and S. Kathryn Rouan, Ph.D.) for terms expiring in 2029.

• Ratification of CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay) for named executive officers.

• Board recommends voting “For” all proposals.

• Shareholder proposals for the 2027 annual meeting must be submitted by December 2, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• Board consists of six members divided into three staggered classes; only one class is elected each year.

• Majority of directors are independent under Nasdaq rules; CEO is not independent.

• Board leadership is separated, with an independent Chairperson.

• Board met eight times in 2025; all directors attended at least 75% of meetings.

• Standing committees: Audit, Compensation, and Nominating and Corporate Governance, all comprised of independent directors.

• Board has adopted a Code of Conduct and Ethics and an Insider Trading Policy.